Ozempic Vs. Zepbound: Fact-Checking Serena Williams' Weight Loss Medication Confession
By Chloe Bennett
The public tendency to label every visible Hollywood or athletic slim-down as an "Ozempic body" stems from Novo Nordisk’s early market dominance. Semaglutide, approved under the brand names Ozempic for type 2 diabetes and Wegovy for chronic weight management, captured global headlines in late 2022. By early 2024, the brand name had become a generic verb, much like Xerox or Kleenex.
That colloquial habit misdiagnosed Williams’ actual regimen. Eli Lilly’s Zepbound operates on a different pharmacological pathway. While semaglutide acts strictly as a GLP-1 receptor agonist, tirzepatide stimulates both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Clinical data from the SURMOUNT trials showed that this dual agonism yields higher average reductions in total body mass, often exceeding 20% to 25% of baseline weight, compared to roughly 15% typically observed with semaglutide.
When sports commentators seized on her appearance, they recycled the dominant catchphrase. The clinical reality was that Williams chose a newer dual-incretin peptide designed to address metabolic resistance that resisted conventional physical conditioning.
Chloe Bennett explores the intersection of pop culture, streaming entertainment, digital trends, and contemporary lifestyle. Her weekly commentary reaches thousands of culture enthusiasts.
